

A Cyclization Reaction Catalysed by Antibodies

Tomoya Kitazume* and Mitsunori Takeda

Department of Bioengineering, Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama 226, Japan

Monoclonal antibodies, elicited by transition-state analogues for either *exo*- or *endo*-lactonization of α -trifluoromethyl- γ,δ -unsaturated acids, catalyse the regioselective formation of corresponding γ - or δ -lactones; the *exo*-lactonization proceeds with high diastereospecificity.

The use of antibodies as selective catalysts in various types of organic reactions has attracted the interest of organic chemists.¹⁻⁵ Recently, disfavoured chemical reactions catalysed by an antibody have been reported.⁶ To date, acid-catalysed cyclization of unsaturated carboxylic acids is a reaction that has been used relatively infrequently in synthesis, particularly from the view point of stereocontrol.⁷ Further, optically pure lactones possessing a fluoromethyl group have been receiving much attention in biological evaluation.⁸ Accordingly, we have investigated the possibility of achieving stereocontrol in the cyclization of γ,δ -unsaturated acids by use of catalytic antibodies.


Enzyme-like catalyst design (antibody reagent design) requires the preparation of haptens with structures that mimic the transition state of the reaction. To form the desired antibody reagents, the immunogenic conjugate was prepared by reaction of the haptens with a carrier protein [bovine serum albumin (BSA) and keyhole limpet haemocyanin (KLH)].^{9,10} Lymphocytes from the spleen of BALB/c mice immunized with each of the purified antigens (the KLH-hapten conjugate) were fused by standard protocols using mouse myeloma cells (P3/NS1/1-Ag4-1) as the fusion partner. Antibodies were screened by ELISA for cross-reactivity with the KLH-hapten conjugate, *i.e.* for inhibition of binding to the KLH-hapten conjugate by free hapten.

To prove the cyclization model, we employed as haptens cyclic ethers bearing a sulfoxide group (Scheme 1). When the antibody binds an electron-rich alkene, the produced acidic site¹¹ is correctly aligned to promote cyclization, thereby catalysing the lactonization of γ,δ -unsaturated acids. The antigen obtained from *trans*-iodo- γ -lactone **2** $\{[\alpha]_D^{21} +9.25$ (*c.* 1.14, MeOH), >94% ee, >98% de¹² produced five antibodies, that from *cis*-iodo- γ -lactone **2** $\{[\alpha]_D^{21} -4.04$ (*c.* 1.08, MeOH), >94% ee, >98% de¹² produced six antibodies, and that from *trans*-iodo- δ -lactone **7** $\{[\alpha]_D^{21} +6.17$ (*c.* 1.09, MeOH), >97% de¹² produced eight antibodies. Antibodies were purified from ascites fluid by protein A Sepharose 4B affinity chromatography, and were determined to be >95% homogeneous by sodium dodecyl sulfate polyacrylamide gel electrophoresis.

These antibody-catalysed lactonizations were inhibited by the addition of the transition state analogue, compound **3** or **8**. The inhibition constant K_i for the formation of the antibody-transition state analogue complex was determined by measuring

the rate of lactonization of substrate (5 mmol) in the presence of antibody (15 $\mu\text{mol dm}^{-3}$) at varying inhibitor concentrations.

The antibody induced from antigen **5**, derived from the *trans*-iodo- γ -lactone **2**, acted to promote exclusively exocyclic ring closure of γ,δ -unsaturated acid **1** to the *trans*- γ -lactone $\{[\alpha]_D^{21} +14.8$ (*c.* 0.71, CHCl_3)¹², with a selectivity of >97% de (58% yield), and the antibody induced from antigen **5**, derived from the *cis*-iodo- γ -lactone **2**, acted to form the *cis*- γ -lactone $\{[\alpha]_D^{21} -6.01$ (*c.* 0.97, CHCl_3)¹² with a selectivity of >96% de (61% yield).[†] Further, the antibody induced from antigen **9**, derived from the *trans*-iodo- δ -lactone **7** $\{[\alpha]_D^{21} +6.17$ (*c.* 1.09, MeOH), >97% de¹², catalysed the cyclization of γ,δ -unsaturated acid to form the δ -lactone $\{[\alpha]_D^{21} +18.9$ (*c.* 1.07, CHCl_3), >94% ee; δ -lactone: γ -lactone = 93:7, and the antibody induced from antigen **9**, derived from the *cis*-iodo- δ -lactone **7** $\{[\alpha]_D^{21} -11.5$ (*c.* 1.14, MeOH), >96% de¹², acted to form the δ -lactone $\{[\alpha]_D^{21} +18.7$ (*c.* 0.91, CHCl_3); δ -lactone: γ -lactone = 94:6. In these cases, the endocyclic ring closure produces the δ -lactone (>94% ee; >50% yield) in more than 85% selectivity (ratio of δ -lactone: γ -lactone).



Scheme 1 Reagents and conditions: i, iodolactonization: I_2 , MeCN; ii, MeCH_2SH , Et_3N , Et_2O ; MCPBA, CH_2Cl_2 ; iii, diisobutylaluminium hydride, Et_2O , -78°C ; iv, $\text{BrCH}_2\text{CH}_2\text{CO}_2\text{Et}$, NaH, Et_2O ; v, lipase P, H_2O ; vi, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, KLH, phosphate buffer (pH 6.0); vii, dialysis, NaCl buffer, pH 7.4




Table 1 Antibody-catalysed lactonizations

Hapten <i>cis</i> or <i>trans</i>	$K_{\text{cat}}^a/$ min^{-1}	$K_m^a/$ $\mu\text{mol dm}^{-3}$	$K_i/$ $\mu\text{mol dm}^{-3}$	Yield (%)	$[\alpha]_D^{21}$ (<i>c.</i> CHCl_3)	d.r. ^b (% de)
<i>trans</i> - γ -lactone	0.86 ± 0.2	190 ± 40	16 ± 3	58	+14.8 (0.71)	> 97
<i>cis</i> - γ -lactone	0.64 ± 0.2	170 ± 30	15 ± 3	61	-6.01 (0.97)	> 96
δ -lactone ^c	0.81 ± 0.2	180 ± 40	17 ± 3	58	+18.9 (1.07)	

^a Kinetic constants were determined by the method of initial rate data. Kinetic parameters for the lactonization from the Lineweaver-Burk plots were determined. ^b d.r. = diastereoisomeric ratio, determined by ^{19}F NMR (470 MHz) intensities using an NMR shift reagent. ^c Ratio of *trans*- δ -lactone and γ -lactone 93:7.

We are very grateful to Professor S. Watanabe at Chiba University for the molecular modelling studies and his assistance with the NMR experiments.

Received, 26th August 1994; Com. 4/052261

Footnote

† The antibody (15 $\mu\text{mol dm}^{-3}$, Lowry assay, with a molecular weight of 1.5×10^5 for immunoglobulin G) was incubated at 25 °C in 50 ml of phosphate buffer at pH 7.3. (S)-(-)-2-(Trifluoromethyl)pent-4-enoic acid $\{[\alpha]_D^{25} -9.77$ (c. 1.13, MeOH), 0.84 g, 5 mmol} in acetonitrile (5 ml) was stirred at 25–27 °C in this solution. After 15 h of stirring, the antibody was removed by centrifugation; the oily materials were extracted with diethyl ether. On removal of the solvent, the lactone was separated by column chromatography on silica gel.

References

- 1 Reviews: P. G. Schultz, *Angew. Chem., Int. Ed. Engl.*, 1989, **28**, 1283; K. M. Shokat and P. G. Schultz, *Annu. Rev. Immunol.*, 1990, **8**, 335; P. G. Schultz, R. A. Lerner and S. J. Benkovic, *Chem. Eng. News*, 1990, **68**, 26.
- 2 A. D. Napper, S. J. Benkovic, A. Tramontano and R. A. Lerner, *Science*, 1987, **237**, 1041; S. J. Benkovic, A. D. Napper and R. A. Lerner, *Proc. Natl. Acad. Sci. USA*, 1988, **85**, 5355; D. Y. Jackson, J. W. Jacobs, R. Sugawara, S. H. Reich, P. A. Bartlett and P. G. Schultz, *J. Am. Chem. Soc.*, 1988, **110**, 4841; D. Hilvert, S. H. Carpenter, K. D. Nared and M. T. M. Auditor, *Proc. Natl. Acad. Sci. U.S.A.*, 1988, **85**, 4953; A. C. Braisted and P. G. Schultz, *J. Am. Chem. Soc.*, 1990, **112**, 7430.
- 3 G. R. Nakayama and P. G. Schultz, *J. Am. Chem. Soc.*, 1992, **114**, 780; J.-L. Reymond, K. D. Janda and R. A. Lerner, *J. Am. Chem. Soc.*, 1992, **114**, 2257; T. Uno and P. G. Schultz, *J. Am. Chem. Soc.*, 1992, **114**, 6573; J. A. Ashley and K. D. Janda, *J. Org. Chem.*, 1992, **57**, 6691.
- 4 T. Kitazume, J.-T. Lin, M. Takeda and T. Yamazaki, *J. Am. Chem. Soc.*, 1991, **113**, 2123; T. Kitazume, J.-T. Lin, T. Yamamoto and T. Yamazaki, *J. Am. Chem. Soc.*, 1991, **113**, 8573; T. Kitazume, T. Tsukamoto and K. Yoshimura, *J. Chem. Soc., Chem. Commun.*, 1994, 1355.
- 5 L. J. Liotta, P. A. Benkovic, G. P. Miller and S. J. Benkovic, *J. Am. Chem. Soc.*, 1993, **115**, 350; Y.-C. J. Chen, T. Danon, L. Sastry, M. Mubarak, K. D. Janda and R. A. Lerner, *J. Am. Chem. Soc.*, 1993, **115**, 357.
- 6 K. D. Janda, C. G. Shevlin and R. A. Lerner, *Science*, 1993, **259**, 490.
- 7 *Asymmetric Synthesis*, ed. J. D. Morrison, Academic, New York, 1984, vol. 3.
- 8 K. Murata, S. Kaneko and T. Kitazume, *Bioorg. & Med. Chem. Lett.*, 1993, **3**, 2685.
- 9 T. Nishima, A. Tsuji and D. Fukushima, *Steroids*, 1974, **24**, 4155.
- 10 H. L. Niman and J. H. Elder, *Proc. Natl. Acad. Sci. USA*, 1980, **77**, 5624.
- 11 N. Janjic and A. Tramontano, *J. Am. Chem. Soc.*, 1989, **111**, 9109; K. M. Shokat, C. J. Leumann, R. Sugawara and P. G. Schultz, *Nature (London)*, 1989, **338**, 269; K. D. Janda, M. I. Weinhouse, D. M. Schloeder and R. A. Lerner, *J. Am. Chem. Soc.*, 1990, **112**, 1274.
- 12 S. Watanabe, Y. Sakai, T. Kitazume and T. Yamazaki, *J. Fluorine Chem.*, 1994, **67**, 149.